Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 4:09 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 25 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: anecortave acetate Clear all
Completed Phase 3 Interventional

Anecortave Acetate in Patients With Exudative Age-related Macular Degeneration (AMD)

NCT00299507
View directory record Official record
Conditions
Macular Degeneration
Interventions
Anecortave Acetate Sterile Suspension, 30 mg/mL, Anecortave Acetate Sterile Suspension, 60 mg/mL, Anecortave Acetate Vehicle
Drug · Other
Lead sponsor
Alcon Research
Industry
Eligibility
50 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Nov 28, 2012 · Synced Oct 21, 2026, 4:09 AM EDT
Completed Phase 1Phase 2 Interventional

Treatment of Chronic Central Serous Chorioretinopathy With Open-Label Anecortave Acetate

NCT00489840
View directory record Official record
Conditions
Chronic Central Serous Chorioretinopathy
Interventions
Anecortave Acetate Sterile suspension 15 mg, Anecortave Acetate
Drug
Lead sponsor
Manhattan Eye, Ear & Throat Hospital
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 25, 2012 · Synced Oct 21, 2026, 4:09 AM EDT
Completed Phase 2 Interventional

Treatment of Pseudovitellium Detachment With Open-Label Anecortave Acetate Sterile Suspension (15 mg)

NCT00211432
View directory record Official record
Conditions
Pseudovitellium Detachment, Eye Diseases
Interventions
Anecortave Acetate Sterile Suspension (15 mg)
Drug
Lead sponsor
Manhattan Eye, Ear & Throat Hospital
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 25, 2012 · Synced Oct 21, 2026, 4:09 AM EDT
Completed Phase 2 Interventional

Treatment of Congenital Telangiectasia (Coat's Disease) With Open-label Anecortave Acetate (15mg.)

NCT00211315
View directory record Official record
Conditions
Coat's Disease
Interventions
anecortave acetate
Drug
Lead sponsor
Manhattan Eye, Ear & Throat Hospital
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 24, 2012 · Synced Oct 21, 2026, 4:09 AM EDT
Completed Phase 2Phase 3 Interventional

Anecortave Acetate Safety in Patients With Open-Angle Glaucoma or Ocular Hypertension

NCT00691717
View directory record Official record
Conditions
Open-angle Glaucoma, Oular Hypertension
Interventions
Anecortave Acetate Sterile Suspension, 30 mg/mL, Anecortave Acetate Sterile Suspension, 60 mg/mL, Anecortave Acetate Sterile Suspension, 75 mg/mL, Anecortave Acetate Vehicle
Drug · Other
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years and older
Enrollment
201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Nov 28, 2012 · Synced Oct 21, 2026, 4:09 AM EDT
Completed Phase 3 Interventional

An Evaluation of Safety and Efficacy of Anecortave Acetate Versus Placebo in Patients With Subfoveal CNV Due to Exudative AMD

NCT00058994
View directory record Official record
Conditions
Macular Degeneration, Maculopathy, Age-Related
Interventions
anecortave acetate
Drug
Lead sponsor
Alcon Research
Industry
Eligibility
50 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Nov 29, 2012 · Synced Oct 21, 2026, 4:09 AM EDT
Completed Phase 3 Interventional

Phase 3 Study to Evaluate Anecortave Acetate vs. Visudyne for the Treatment of the Wet Form of AMD

NCT00041483
View directory record Official record
Conditions
Macular Degeneration
Interventions
Anecortave Acetate 15 mg sterile suspension, Photodynamic Therapy (PDT)
Drug · Other
Lead sponsor
Alcon Research
Industry
Eligibility
50 Years and older
Enrollment
530 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Jul 1, 2014 · Synced Oct 21, 2026, 4:09 AM EDT
Completed Phase 1 Interventional

Study of the Combination of Anecortave Acetate and Triamcinolone Acetonide for the Treatment of Exudative Age-Related Macular Degeneration (AMD)

NCT00211419
View directory record Official record
Conditions
Maculopathy, Age-Related
Interventions
Anecortave Acetate 15 mg, Triamcinolone Acetate 4 mg, Photodynamic Therapy with Verteporfin, Thermal Laser
Drug · Procedure
Lead sponsor
Manhattan Eye, Ear & Throat Hospital
Other
Eligibility
50 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 24, 2012 · Synced Oct 21, 2026, 4:09 AM EDT
Completed Phase 2 Interventional

Treatment of Idiopathic Perifoveal Telangiectasia (IPT) With Open-Label Anecortave Acetate (15mg.).

NCT00211328
View directory record Official record
Conditions
Idiopathic Perifoveal Telangiectasia
Interventions
anecortave acetate
Drug
Lead sponsor
Manhattan Eye, Ear & Throat Hospital
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 4, 2009 · Synced Oct 21, 2026, 4:09 AM EDT
Completed Phase 1 Interventional

Prophylactic Anecortave Acetate in Patients With a Retisert Implant

NCT00570479
View directory record Official record
Conditions
Uveitis, Posterior, Glaucoma
Interventions
anecortave acetate
Drug
Lead sponsor
Texas Retina Associates
Other
Eligibility
10 Years to 80 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Arlington, Texas
Source: ClinicalTrials.gov public record
Updated Jun 5, 2012 · Synced Oct 21, 2026, 4:09 AM EDT
No Longer Available No phase listed Expanded access

Treatment of Patients With Age-Related Macular Degeneration With Anecortave Acetate

NCT00349739
View directory record Official record
Conditions
Macular Degeneration
Interventions
Anecortave Acetate
Drug
Lead sponsor
University of Iowa
Other
Eligibility
55 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Jan 15, 2010 · Synced Oct 21, 2026, 4:09 AM EDT
Terminated Phase 3 Interventional

Open-Label Posterior Juxtascleral Injections of Anecortave Acetate 15mg Dose for Long Term Use in Patients With AMD

NCT00065728
View directory record Official record
Conditions
Macular Degeneration
Interventions
Anecortave Acetate (AL-3789) Sterile Suspension, 30 mg/mL
Drug
Lead sponsor
Alcon Research
Industry
Eligibility
50 Years and older
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
1
States / cities
Central Contact Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Sep 16, 2013 · Synced Oct 21, 2026, 4:09 AM EDT
Terminated Not applicable Interventional Results available

Anecortave Acetate Injection to Treat Steroid-responsive Intraocular Pressure Increase in Cornea Transplant Patients

NCT00884039
View directory record Official record
Conditions
Transplant, Intraocular Pressure
Interventions
anecortave acetate, 30 mg anecortave acetate
Drug
Lead sponsor
Cornea Research Foundation of America
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Aug 14, 2018 · Synced Oct 21, 2026, 4:09 AM EDT
Completed Phase 2 Interventional

Anecortave Acetate Versus Placebo in AMD Patients Following PDT

NCT00346866
View directory record Official record
Conditions
AMD
Interventions
anecortave acetate
Drug
Lead sponsor
Alcon Research
Industry
Eligibility
50 Years and older
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2001
U.S. locations
1
States / cities
Beachwood, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 5, 2008 · Synced Oct 21, 2026, 4:09 AM EDT
Terminated Phase 2 Interventional

Treatment of Rubeosis Iridis With Open-Label Anecortave Acetate Sterile Suspension ( 15 mg.).

NCT00211471
View directory record Official record
Conditions
Severe Diabetic Retinopathy, Central Retinal Vein Occlusion, Chronic Inflammation, Infectious Diseases
Interventions
anecortave acetate
Drug
Lead sponsor
Manhattan Eye, Ear & Throat Hospital
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 7, 2007 · Synced Oct 21, 2026, 4:09 AM EDT
Withdrawn Phase 2 Interventional

Treatment of Retinal Vein Occlusion (RVO) With Open-Label Anecortave Acetate (15mg.)

NCT00211354
View directory record Official record
Conditions
Retinal Vein Occlusion
Interventions
Anecortave Acetate
Drug
Lead sponsor
Manhattan Eye, Ear & Throat Hospital
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 4, 2009 · Synced Oct 21, 2026, 4:09 AM EDT
Terminated Phase 1 Interventional

Treatment of Diabetic Retinopathy With Open-Label Anecortave Acetate Sterile Suspension (15 mg)

NCT00211406
View directory record Official record
Conditions
Diabetic Retinopathy
Interventions
Anecortave Acetate Sterile Suspension (15 mg)
Drug
Lead sponsor
Manhattan Eye, Ear & Throat Hospital
Other
Eligibility
18 Years and older
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 8, 2007 · Synced Oct 21, 2026, 4:09 AM EDT
Completed Phase 2 Interventional

Treatment of Age-Related Macular Degeneration With Anecortave Acetate

NCT00211458
View directory record Official record
Conditions
Macular Degeneration
Interventions
Anecortave Acetate Sterile Suspension (15 mg)
Drug
Lead sponsor
Manhattan Eye, Ear & Throat Hospital
Other
Eligibility
50 Years and older
Timeline
2005 – 2007
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 25, 2012 · Synced Oct 21, 2026, 4:09 AM EDT
Completed Phase 2 Interventional

Treatment of Conditions With Open Label-Anecortave Acetate Sterile Suspension ( 15mg.) Where Lesions do Not Meet Acceptable Criteria for Standard Care.

NCT00211484
View directory record Official record
Conditions
Age-Related Macular Degenerations., Subfoveal Neovascularization.
Interventions
Anecortave Acetate
Drug
Lead sponsor
Manhattan Eye, Ear & Throat Hospital
Other
Eligibility
18 Years and older
Enrollment
5 participants
Timeline
2003 – 2007
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 7, 2007 · Synced Oct 21, 2026, 4:09 AM EDT
Terminated Phase 3 Interventional

Anecortave Acetate Risk-Reduction Trial (AART)

NCT00307398
View directory record Official record
Conditions
Dry AMD
Interventions
Anecortave Acetate (AL-3789) sterile suspension, 15 mg or 30 mg, Anecortave Acetate Vehicle
Drug · Other
Lead sponsor
Alcon Research
Industry
Eligibility
50 Years and older
Enrollment
2,596 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Nov 28, 2012 · Synced Oct 21, 2026, 4:09 AM EDT
Completed Phase 2 Interventional

Safety and Efficacy of Anecortave Acetate in Patients With Open-Angle Glaucoma

NCT00451152
View directory record Official record
Conditions
Open-angle Glaucoma
Interventions
Anecortave Acetate Sterile Suspension, 30 mg/mL, Anecortave Acetate Vehicle
Drug · Other
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years and older
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Nov 28, 2012 · Synced Oct 21, 2026, 4:09 AM EDT
Terminated Phase 2 Interventional

A Dose-Volume Study of a Treatment for Elevated IOP Due to Open-Angle Glaucoma or Ocular Hypertension

NCT00788541
View directory record Official record
Conditions
Open-Angle Glaucoma, Ocular Hypertension
Interventions
Anecortave Acetate Sterile Suspension, 6 mg/mL, Anecortave Acetate Sterile Suspension, 3.75 mg/mL, Anecortave Acetate Sterile Suspension, 96 mg/mL, Anecortave Acetate Sterile Suspension, 60 mg/ML, Anecortave Acetate Vehicle
Drug · Other
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years and older
Enrollment
197 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Nov 30, 2012 · Synced Oct 21, 2026, 4:09 AM EDT
Terminated Phase 3 Interventional

Anecortave Acetate Risk-Reduction Trial (AART)

NCT00333216
View directory record Official record
Conditions
AMD
Interventions
Anecortave Acetate Sterile Suspension, 30 mg/mL, Anecortave Acetate Sterile Suspension, 60 mg/ML, Anecortave Acetate Vehicle
Drug · Other
Lead sponsor
Alcon Research
Industry
Eligibility
50 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Nov 28, 2012 · Synced Oct 21, 2026, 4:09 AM EDT
Completed Phase 2 Interventional

Anecortave Acetate for Treatment of Steroid Induced Intraocular Pressure (IOP) Elevation

NCT00315640
View directory record Official record
Conditions
Eye Diseases
Interventions
Anecortave Acetate Sterile Suspension, 6 mg/mL, Anecortave Acetate Suspension Depot, 30 mg/mL, Anecortave Acetate Sterile Suspension, 60 mg/mL, Anecortave Acetate Vehicle
Drug · Other
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
5
States / cities
Jacksonville, Florida • Miami, Florida • Detroit, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 28, 2012 · Synced Oct 21, 2026, 4:09 AM EDT